{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:33:28Z","timestamp":1792859608258,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Observations highlighting the \u201cunmasking\u201d of cutaneous T-cell lymphoma after treatment with dupilumab for atopic dermatitis (AD) have been recently reported. However, there remains a paucity of literature describing the evolution of clinical and histopathological features that characterizes this phenomenon.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To define the clinical and histopathologic evolution of atypical lymphoid infiltrates after the administration of dupilumab for AD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A cross-sectional study of clinical and histopathologic features in 7 consecutive patients with a diagnosis of \u201catypical lymphoid infiltrate\u201d or mycosis fungoides (MF) on dupilumab for AD was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seven patients with atypical lymphoid infiltrates or MF in evolution after dupilumab therapy (age range 27\u201374 years) were reviewed. Average duration of AD before MF diagnosis was 5.7 years, and the average duration on dupilumab treatment was 9.8 months. Notable histopathologic features across predupilumab and postdupilumab biopsies included progressive increase in the densities of the atypical lymphoid infiltrates (7\/7), presence of atypical epidermotropic lymphocytes (6\/7), and papillary dermal fibrosis (6\/7).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Limitations:<\/jats:title>\n            <jats:p>Small retrospective cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>These cases highlight the transformation of lymphoid infiltrates after dupilumab treatment for AD and emphasize the importance of clinical and histopathologic evaluation before and during treatment with dupilumab for treatment-refractory presumed AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000001875","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T15:14:51Z","timestamp":1623856491000},"page":"714-720","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates"],"prefix":"10.1097","volume":"43","author":[{"given":"Olayemi","family":"Sokumbi","sequence":"first","affiliation":[{"name":"Departments of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic Jacksonville, Jacksonville, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Shamim","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Dennis P.","family":"Davis","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wetter","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Newman","sequence":"additional","affiliation":[{"name":"Dermatology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneka","family":"Comfere","sequence":"additional","affiliation":[{"name":"Dermatology, and"},{"name":"Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/jid.2012.13","article-title":"Molecular markers of early-stage mycosis fungoides","volume":"132","author":"Zhang","year":"2012","journal-title":"J Invest Dermatol."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2133.2003.05551.x","article-title":"Cutaneous T-cell lymphoma and atopy: is there an association?","volume":"149","author":"Mehrany","year":"2003","journal-title":"Br J Dermatol."},{"issue":"3 suppl 1","key":"R4-20250616","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"9717530","DOI":"10.1155\/2016\/9717530","article-title":"S\u00e9zary syndrome and atopic dermatitis: comparison of immunological aspects and targets","volume":"2016","author":"Saulite","year":"2016","journal-title":"Biomed Res Int."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/cup.13142","article-title":"Appropriate use criteria in dermatopathology: initial recommendations from the American Society of Dermatopathology","volume":"45","author":"Vidal","year":"2018","journal-title":"J Cutan Pathol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/jclinpath-2018-205004","article-title":"Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma","volume":"71","author":"Rea","year":"2018","journal-title":"J Clin Pathol."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5732\/cjc.010.10344","article-title":"Diagnostic significance of TCR gene clonal rearrangement analysis in early mycosis fungoides","volume":"30","author":"Xu","year":"2011","journal-title":"Chin J Cancer."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bjd.14017","article-title":"Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group","volume":"173","author":"Hurabielle","year":"2015","journal-title":"Br J Dermatol."},{"key":"R15-20250616","first-page":"949","article-title":"From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors","volume":"137","author":"Burg","year":"2001","journal-title":"Arch Dermatol."},{"issue":"1 suppl","key":"R16-20250616","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1038\/jid.1995.21","article-title":"Lymphocyte activation in cutaneous T-cell lymphoma","volume":"105","author":"Wood","year":"1995","journal-title":"J Invest Dermatol."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1523-1747.ep12388985","article-title":"Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile","volume":"103","author":"Saed","year":"1994","journal-title":"J Invest Dermatol."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/1523-1747.ep12326693","article-title":"Th2 cytokine profile in cutaneous T-cell lymphoma","volume":"105","author":"Lessin","year":"1995","journal-title":"J Invest Dermatol."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2020.03.051","article-title":"Dupilumab and cutaneous T-cell lymphoma","volume":"83","author":"Elston","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0190-9622(89)70174-2","article-title":"Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases","volume":"21","author":"Oliver","year":"1989","journal-title":"J Am Acad Dermatol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J Dermatolog Treat."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:04:44Z","timestamp":1750100684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001875","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}